Story thread · 3 reports / 2 sources

Healthcare Briefs: Forte Biosciences Acquired In $2.2 Billion Deal By Amsterdam-based Agenx

dmagazine.com · 12dShare

Dallas-based Forte Biosciences has been acquired by Amsterdam-based Agenx, a global immunology company, for $2.2 billion. The move adds Forte’s lead investigational therapy FB102 to Agenx’s immunology pipeline. FB102 is a first-in-class anti-CD122 antibody being developed to treat autoimmune diseases, including vitiligo and celiac disease, with additional potential applications in other immune-mediated conditions. The acquisition is … Continued The post Healthcare Briefs: Forte Biosciences Acquired In $2.2 Billion Deal By Amsterdam-based Agenx appeared first on D Magazine .

First report: argenx Bets $2.2 Billion on a Vitiligo Breakthrough: What the Forte Biosciences Deal Means for Both Stocks — finance.yahoo.com, 13d